5-Amino-1MQ: Fat-Loss Claims and Reported Doses
Fat-loss claims · capsules vs injections
People look into 5-amino-1MQ hoping to lose fat without suppressing appetite. Oral capsules also appeal to people who want fewer injections. Human results have not caught up with those promises.
The supporting fat-loss studies are in mice. They do not establish meaningful weight loss, muscle preservation or a safe human regimen.
Same name, different route
Capsule Gut absorption Blood exposure
Injection Absorption from tissue Blood exposure
There is no verified human dose conversion between these routes.
Reported amounts: keep the route attached
Jay Campbell’s 2023 book describes 50–150 mg orally once daily with food, for 20–30 days followed by a 1–2-week break. That is one author’s reported-use example, not a human trial or an established safe cycle.
50–150 mg
Oral amount
Once daily with food in the book example.
20–30 days
Reported course
The author describes a 1–2-week break afterward; this does not establish recovery or safety.
Do not convert that oral amount into an injection amount. Human absorption and formulation comparisons remain unresolved.
What 5-amino-1MQ actually is
The full name is 5-amino-1-methylquinolinium. It is not a peptide, despite appearing in peptide catalogs. Its target, nicotinamide N-methyltransferase (NNMT), converts nicotinamide into a methylated product. Researchers are investigating whether reducing that activity changes fat-cell metabolism.
In plain terms, the idea is to change how fat cells handle energy. That is different from demonstrating that someone loses fat, keeps muscle or tolerates a product well. It also does not make 5-amino-1MQ an interchangeable substitute for a GLP-1 medicine.
What the animal research shows
The foundational paper is a 2018 Biochemical Pharmacology study, not a Journal of Medicinal Chemistry human trial. In one experiment, diet-induced obese mice received subcutaneous treatment three times daily for 11 days. Body weight and fat-tissue measures fell without a detected reduction in food intake. The route and short duration matter: this experiment does not validate an oral supplement schedule. Original study.
A later mouse investigation extended the work to obesity-related metabolic abnormalities. It still studied an animal model; it did not establish a human weight-loss effect. Subsequent study.
How to compare the claims you see
| Claim on a product page | What would establish it? |
|---|---|
| “Raises NAD+” | A measured change in the relevant tissue and population, not simply an enzyme diagram |
| “Works orally” | Absorption and exposure data for that oral formulation |
| “Burns fat without dieting” | A controlled human study measuring body composition and food intake |
| “Benefits women” | Human outcomes and safety data that actually address that population |
The human evidence reviewed for this update does not establish those clinical promises. Being a small molecule does not, by itself, guarantee oral absorption. Likewise, a seller’s certificate may describe a tested sample without establishing a treatment’s effectiveness.
What the half-life number means
A number entered into a plotter can show what would happen if that assumption were true. The primary studies above do not provide a measured human half-life that validates a personal dosing interval. Read the model notes on the compound page before treating an illustrative curve as expected blood levels.
Frequently asked questions
Is it the same as NR or NMN? No. Those names refer to NAD-related precursors; 5-amino-1MQ acts on an enzyme. Sharing a metabolic theme does not establish interchangeable effects or a beneficial combination.
Are there demonstrated benefits specifically for women? The cited work does not establish a female-specific human benefit or regimen. A female-specific regimen cannot be inferred from an animal weight-loss result.
Is it an approved weight-loss medicine? No approved weight-loss indication is established by this research. A research-chemical listing is not a prescription label. For a treatment decision, compare options supported by human trials with a clinician.
Can I use the mouse amount to calculate a human dose? No. A body-weight conversion would still leave absorption, formulation, long-term exposure and human tolerability unresolved.
Sources and research scope
- Neelakantan et al., 2018: enzyme/cell experiments and short-term treatment of obese mice.
- Nicotinamide N-methyltransferase inhibition and metabolic dysfunction: later preclinical investigation; no human regimen established.
Related compounds & model context
Article citations are linked in the text. Related catalog entries have separate model inputs and source notes, which may include unverified estimates. See our methodology for model assumptions and limitations.